What oral contraceptive (birth control) brands are commonly used in the United States, and what are their generic names and typical dosing schedules?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Oral Contraceptive Brands and Formulations in the United States

Most Commonly Used Oral Contraceptives

The most commonly prescribed oral contraceptive brands in the U.S. contain norgestimate (32% of users) or norethindrone (20% of users) as the progestin component, combined with ethinyl estradiol in doses of ≥30 mcg (used by 67% of COC users) or <20-30 mcg (used by 33% of COC users). 1

Major Categories of Oral Contraceptives

Combined Hormonal Contraceptives (CHCs)

  • Monophasic formulations (67% of users) deliver the same hormone dose daily, while multiphasic formulations (33% of users) vary hormone levels throughout the cycle 1
  • Traditional 21/7 regimens (88% of users) provide 21 days of active pills followed by 7 days of placebo 1
  • Extended-cycle regimens (12% of users) include:
    • 24/4 regimens: 24 active days + 4 placebo days, available as ethinyl estradiol 20 mcg-drospirenone 3 mg or ethinyl estradiol 20 mcg-norethindrone 1 mg 2
    • 84/7 regimens: 84 active days + 7 placebo days (menses 4 times/year), available as ethinyl estradiol 30 mcg-levonorgestrel 150 mcg, with or without low-dose ethinyl estradiol (10 mcg/day) during the 7-day interval 2
    • Continuous regimens: ethinyl estradiol 20 mcg-levonorgestrel 90 mcg taken daily without placebo 2

Progestin-Only Pills (POPs)

  • Norethindrone or norgestrel POPs: Require backup contraception for 2 days if started >5 days after menses 3
  • Drospirenone POPs: Require backup contraception for 7 days if started >1 day after menses 3

Initiation Guidelines

Combined Hormonal Contraceptives

  • Start anytime if reasonably certain the patient is not pregnant 3
  • Backup contraception needed: If started >5 days after menses, use barrier methods for 7 days 3
  • Required pre-initiation assessment: Blood pressure measurement only 3

Progestin-Only Pills

  • Start anytime without examination 3
  • Backup contraception timing: 2 days for norethindrone/norgestrel, 7 days for drospirenone if not started within the specified window after menses 3

Clinical Effectiveness and Safety

  • Typical-use failure rates: 7-9% per year for both CHCs and POPs, with perfect-use rates of 4-7% 4, 5
  • Venous thromboembolism risk: CHCs increase risk from 2-10 events per 10,000 women-years to 7-10 events per 10,000 women-years 5
  • Progestin-only methods: Associated with rare serious risks, making them safer alternatives for patients with cardiovascular risk factors 5

Common Pitfalls

  • Extended-cycle formulations cause more breakthrough bleeding and spotting than traditional 21/7 regimens, though this typically improves over time 2
  • Drug interactions: Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine) and rifampin/rifabutin reduce CHC and POP effectiveness (Category 3*), requiring alternative contraception or backup methods 3
  • Lamotrigine interaction: CHCs are Category 3* with lamotrigine due to decreased lamotrigine levels, potentially reducing seizure control 3
  • Broad-spectrum antibiotics, antifungals, and antiparasitics do not reduce oral contraceptive effectiveness (Category 1) 3

Noncontraceptive Benefits

  • Cancer risk reduction: Decreased ovarian and endometrial cancer risk 4
  • Menstrual symptom improvement: Effective for acne, menstruation-related migraines, premenstrual dysphoric disorder, and endometriosis 4, 5
  • Bleeding pattern control: More predictable and often lighter menses 4

References

3
Guideline

u.s. selected practice recommendations for contraceptive use, 2024.

MMWR Recommendations and Reports, 2024

Related Questions

What is the appropriate management for a patient with a blood pressure of 210/120 mmHg?
What are the five components of the Babinski (extensor plantar) response?
Is a unilateral pulsatile sensation in the ear of a mother who is 1 week postpartum and breastfeeding a normal physiologic finding or does it require further evaluation?
What are the observable seizure manifestations in the 2025 ILAE classification?
What is the appropriate evaluation and management for a 24‑year‑old female presenting with dysuria without burning, normal urine color, and no other symptoms?
What is the optimal treatment for an elderly patient with green sputum indicating a likely bacterial lower respiratory infection?
What does a urine leukocyte esterase result of +3 indicate and how should it be managed?
Can propranolol (as needed) help obsessive‑compulsive disorder symptoms?
What tests are used to evaluate a mixed germ cell tumor?
What adjunctive treatments can be added to sertraline (Zoloft) for a patient who remains symptomatic despite maximal dosing?
What is the recommended treatment strategy for a patient with elevated lipoprotein(a) and high atherosclerotic cardiovascular risk?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.